<DOC>
	<DOCNO>NCT02225002</DOCNO>
	<brief_summary>CD40 , member Tumor Necrosis Factor receptor superfamily , express many tumor type , include melanoma , prostate , colon , breast , renal , pancreatic , nonsmall cell lung cancer . In preclinical model , activation CD40 result increase antigen presentation induction apoptosis . CD40 also express antigen presenting cell ( APCs ) ( B cell , dendritic cell , monocyte ) key regulator cellular humoral immune response . Activation CD40 CP-870,893 , agonistic anti-CD40 monoclonal antibody , enhance host immune response abrogate growth tumor independently expression CD40 tumor cell . Therefore , hypothesize therapeutic intervention CP-870,893 may beneficial large number cancer patient either immunomodulatory effect direct effect CD40-positive tumor cell .</brief_summary>
	<brief_title>Phase 1 , Open-Label , Dose-Escalation Study CP-870,893 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Men woman least 18 year old advance solid tumor relapse refractory standard therapy effective therapy exist ; Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 ; Adequate bone marrow function document within 2 week prior treatment , define : White blood cell ( WBC ) count &gt; 3000 cells/μL without growth factor support ; Absolute neutrophil count ( ANC ) ≥1500/μL without growth factor support ; Platelets &gt; 100,000/μL without growth factor support ; Hemoglobin ≥10 g/dL ; Ddimer WNL ; Adequate renal hepatic function document within 2 week prior treatment , define : Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) ; Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 × ULN ; Creatinine clearance ( CLcr , measure calculate ) &gt; 80 mL/min ; Life expectancy least 12 week ; Fully recover acute effect prior cancer therapy : 4 week chemotherapy ( 8 week mitomycin C nitrosoureas ) , 10 day prior palliative radiation therapy hormonal therapy , 4 week prior immunotherapy biologic therapy ; Signed write informed consent . Previously treat agent target CD40 ; Concurrent treatment anticancer agent ; History autoimmune disorder , include pemphigus vulgaris , systemic mastocytosis , systemic lupus erythamatosus , dermatomyositis/polymyositis , rheumatoid arthritis , systemic sclerosis , Sjörgen 's syndrome , vasculitis/arteritis , Behcet 's syndrome , inflammatory boweldisease , autoimmune thyroiditis , multiple sclerosis , chronic inflammatory disease ; Treatment investigational therapy within 4 week prior baseline ; History ( within previous year ) congestive heart failure , stroke , myocardial infarction ; Patients know hereditary acquire coagulopathies ( eg . hemophilia , von Willebrand 's disease , cancerassociated DIC , abnormal Ddimer ) ; Patients know brain metastasis . Patients clinical evidence suggestive new brain metastasis prior enrollment exclude brain metastasis rule via CT MRI . Patients previously diagnose brain metastasis eligible complete CNS treatment recover acute effect radiation therapy surgery prior start study medication , discontinue corticosteroid treatment metastasis least 4 week , neurologically stable ; Patients reproductive potential use effective method birth control pregnant breastfeed positive ( urine serum ) pregnancy test baseline ; Known sensitivity immunomodulating agent monoclonal antibody ; Alcohol abuse illicit drug use within 12 month enrollment ; History serum creatinine ≥2 mg/dL duration reason ; Patients , menstruate female , urine dipstick 1+ positive blood 2+ positive protein ; Patients clinically significant presence granular cellular cast centrifuge urine sediment ; Patients renal carcinoma renal metastasis ; Patients partial complete nephrectomy ; Patients require dialysis ( peritoneal hemodialysis ) ; Prior treatment Amphotericin B cisplatin ; Patients history insulindependent diabetes great 5 year ; Concomitant treatment systemic high dose corticosteroid treatment systemic corticosteroid within 4 week baseline ; Concomitant treatment anticoagulant , coumadin heparin , except maintain patency indwell catheter ; Prior allergic reaction attribute compound similar chemical biologic composition study drug ( eg , rituximab immunoglobulin G ) ; Ongoing active infection ; Required use systemic antibiotic antifungal ongoing recurrent infection . Topical use antibiotic antifungal allow ; Other uncontrolled concurrent illness would preclude study participation ; Psychiatric illness social situation would preclude study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>relapse</keyword>
	<keyword>refractory standard therapy</keyword>
	<keyword>effective therapy exists</keyword>
</DOC>